BioMS Medical expands multiple sclerosis trial into Spain, Germany

By Jennifer Chiou

New York, Sept. 7 - BioMS Medical Corp. announced the expansion of its phase 2/3 clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis into Spain and Germany.

On Aug. 16, the Edmonton, Alta., biotechnology company had ongoing trial sites across Canada, the United Kingdom, Sweden, Denmark and the Netherlands.

To date, BioMS Medical said it has received recommendations to continue the trial after five regularly scheduled reviews by the data safety monitoring board.

The purpose of the board is to provide objective, independent safety monitoring of the trial.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.